Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Quality of life in second-line treatment of metastatic renal cell carcinoma with Everolimus : EVERPRO

Trial Profile

Quality of life in second-line treatment of metastatic renal cell carcinoma with Everolimus : EVERPRO

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Jan 2019

At a glance

  • Drugs Everolimus (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms EVERPRO
  • Most Recent Events

    • 19 Jan 2019 Results evaluating the quality of life in second-line treatment of metastatic renal cell carcinoma with everolimus published in the Oncology Research and Treatment
    • 15 Mar 2018 New trial record
    • 10 Feb 2018 Results presented at the 2018 Genitourinary Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top